PIK3CA and head and neck cancer: In addition to this, the concomitant inhibition of PI3K and mTORC1 has been proven to sensitize resistant cell lines in breast and head and neck cancer, suggesting that mTORC1 may play a role in limiting the sensitivity to PI3K30.